197 related articles for article (PubMed ID: 36626583)
1. Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial.
Song Y; Tilly H; Rai S; Zhang H; Jin J; Goto H; Terui Y; Shin HJ; Kim WS; Cao J; Feng J; Eom HS; Kim TM; Tsai XC; Gau JP; Koh H; Zhang L; Song Y; Yang Y; Li W; Huang H; Ando K; Sharman JP; Sehn LH; Bu L; Wang X; Jiang Y; Hirata J; Lee C; Zhu J; Izutsu K
Blood; 2023 Apr; 141(16):1971-1981. PubMed ID: 36626583
[TBL] [Abstract][Full Text] [Related]
2. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.
Tilly H; Morschhauser F; Sehn LH; Friedberg JW; Trněný M; Sharman JP; Herbaux C; Burke JM; Matasar M; Rai S; Izutsu K; Mehta-Shah N; Oberic L; Chauchet A; Jurczak W; Song Y; Greil R; Mykhalska L; Bergua-Burgués JM; Cheung MC; Pinto A; Shin HJ; Hapgood G; Munhoz E; Abrisqueta P; Gau JP; Hirata J; Jiang Y; Yan M; Lee C; Flowers CR; Salles G
N Engl J Med; 2022 Jan; 386(4):351-363. PubMed ID: 34904799
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma.
Kambhampati S; Saumoy M; Schneider Y; Pak S; Budde LE; Mei MG; Siddiqi T; Popplewell LL; Wen YP; Zain J; Forman SJ; Kwak LW; Rosen ST; Danilov AV; Herrera AF; Thiruvengadam NR
Blood; 2022 Dec; 140(25):2697-2708. PubMed ID: 35700381
[TBL] [Abstract][Full Text] [Related]
4. US cost-effectiveness analysis of polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma.
Matasar M; Masaquel A; S Ho R; Launonen A; Ng CD; Wang R; Fox D; Hossain F; Li J; Burke JM
J Med Econ; 2023; 26(1):1134-1144. PubMed ID: 37674384
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of combination therapy of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisolone for previously untreated diffuse large B-cell lymphoma in Japan.
Mizuoka T; Sakamaki H; Fuji S; Saito S; Murata T; Ohno S; Inubashiri N; Oshima T; Yamamoto K
J Med Econ; 2023; 26(1):1122-1133. PubMed ID: 37656225
[TBL] [Abstract][Full Text] [Related]
6. Comparison of statistical methods for extrapolating survival in previously untreated diffuse large B-cell lymphoma: results based on the POLARIX study.
Ho RS; Launonen A
J Med Econ; 2023; 26(1):1178-1189. PubMed ID: 37702406
[TBL] [Abstract][Full Text] [Related]
7. Superiority of polatuzumab vedotin over other novel agents in previously untreated ABC-type diffuse large B-cell lymphoma: a network meta-analysis of 20 RCTs.
Sheng Z; Li D; Chen B; Zhao C; Zhang W; Ding B; Wang L
Ann Hematol; 2023 May; 102(5):1011-1017. PubMed ID: 36947214
[TBL] [Abstract][Full Text] [Related]
8. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
Robak T; Jin J; Pylypenko H; Verhoef G; Siritanaratkul N; Drach J; Raderer M; Mayer J; Pereira J; Tumyan G; Okamoto R; Nakahara S; Hu P; Appiani C; Nemat S; Cavalli F;
Lancet Oncol; 2018 Nov; 19(11):1449-1458. PubMed ID: 30348538
[TBL] [Abstract][Full Text] [Related]
9. Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study.
Tilly H; Morschhauser F; Bartlett NL; Mehta A; Salles G; Haioun C; Munoz J; Chen AI; Kolibaba K; Lu D; Yan M; Penuel E; Hirata J; Lee C; Sharman JP
Lancet Oncol; 2019 Jul; 20(7):998-1010. PubMed ID: 31101489
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma.
Shemesh CS; Agarwal P; Lu T; Lee C; Dere RC; Li X; Li C; Jin JY; Girish S; Miles D; Lu D
Cancer Chemother Pharmacol; 2020 May; 85(5):831-842. PubMed ID: 32222808
[TBL] [Abstract][Full Text] [Related]
11. Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas.
Lynch RC; Poh C; Ujjani CS; Warren EH; Smith SD; Shadman M; Morris K; Lee S; Rasmussen H; Ottemiller S; Shelby M; Keo S; Verni K; Kurtz DM; Alizadeh AA; Chabon JJ; Hogan GJ; Schulz A; Gooley T; Voutsinas JM; Gopal AK
Blood Adv; 2023 Jun; 7(11):2449-2458. PubMed ID: 36521030
[TBL] [Abstract][Full Text] [Related]
12. A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA.
Sehn LH; Martelli M; Trněný M; Liu W; Bolen CR; Knapp A; Sahin D; Sellam G; Vitolo U
J Hematol Oncol; 2020 Jun; 13(1):71. PubMed ID: 32505213
[TBL] [Abstract][Full Text] [Related]
13. Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.
Younes A; Sehn LH; Johnson P; Zinzani PL; Hong X; Zhu J; Patti C; Belada D; Samoilova O; Suh C; Leppä S; Rai S; Turgut M; Jurczak W; Cheung MC; Gurion R; Yeh SP; Lopez-Hernandez A; Dührsen U; Thieblemont C; Chiattone CS; Balasubramanian S; Carey J; Liu G; Shreeve SM; Sun S; Zhuang SH; Vermeulen J; Staudt LM; Wilson W;
J Clin Oncol; 2019 May; 37(15):1285-1295. PubMed ID: 30901302
[TBL] [Abstract][Full Text] [Related]
14. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of polatuzumab vedotin in combination with chemoimmunotherapy (pola-R-CHP) in previously untreated diffuse large B-cell lymphoma in Germany.
Kambhampati S; Shumilov E; Saumoy M; Herrera AF; Tilly H; Lenz G; Thiruvengadam NR
Br J Haematol; 2023 Aug; 202(4):771-775. PubMed ID: 37188351
[TBL] [Abstract][Full Text] [Related]
16. ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma.
Nowakowski GS; Chiappella A; Gascoyne RD; Scott DW; Zhang Q; Jurczak W; Özcan M; Hong X; Zhu J; Jin J; Belada D; Bergua JM; Piazza F; Mócikova H; Molinari AL; Yoon DH; Cavallo F; Tani M; Yamamoto K; Izutsu K; Kato K; Czuczman M; Hersey S; Kilcoyne A; Russo J; Hudak K; Zhang J; Wade S; Witzig TE; Vitolo U
J Clin Oncol; 2021 Apr; 39(12):1317-1328. PubMed ID: 33621109
[TBL] [Abstract][Full Text] [Related]
17. Positron emission tomography-adapted therapy in low-risk diffuse large B-cell lymphoma: results of a randomized, phase III, non-inferiority trial.
Shi Q; He Y; Yi HM; Mu RJ; Jiang XF; Fu D; Dong L; Qin W; Xu PP; Cheng S; Song Q; Chen SJ; Wang L; Zhao WL
Cancer Commun (Lond); 2023 Aug; 43(8):896-908. PubMed ID: 37403255
[TBL] [Abstract][Full Text] [Related]
18. Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.
Vitolo U; Trněný M; Belada D; Burke JM; Carella AM; Chua N; Abrisqueta P; Demeter J; Flinn I; Hong X; Kim WS; Pinto A; Shi YK; Tatsumi Y; Oestergaard MZ; Wenger M; Fingerle-Rowson G; Catalani O; Nielsen T; Martelli M; Sehn LH
J Clin Oncol; 2017 Nov; 35(31):3529-3537. PubMed ID: 28796588
[TBL] [Abstract][Full Text] [Related]
19. Polatuzumab Vedotin for the Front-Line Treatment of Diffuse Large B-Cell Lymphoma: A New Standard of Care?
Davis JA; Shockley A; Herbst A; Hendrickson L
J Adv Pract Oncol; 2023 Jan; 14(1):67-72. PubMed ID: 36741209
[TBL] [Abstract][Full Text] [Related]
20. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.
Horwitz S; O'Connor OA; Pro B; Illidge T; Fanale M; Advani R; Bartlett NL; Christensen JH; Morschhauser F; Domingo-Domenech E; Rossi G; Kim WS; Feldman T; Lennard A; Belada D; Illés Á; Tobinai K; Tsukasaki K; Yeh SP; Shustov A; Hüttmann A; Savage KJ; Yuen S; Iyer S; Zinzani PL; Hua Z; Little M; Rao S; Woolery J; Manley T; Trümper L;
Lancet; 2019 Jan; 393(10168):229-240. PubMed ID: 30522922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
